MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

PURPOSE: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer. PATIENTS AND ME...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Chien, A. Jo, Tripathy, Debasish, Albain, Kathy S., Symmans, W. Fraser, Rugo, Hope S., Melisko, Michelle E., Wallace, Anne M., Schwab, Richard, Helsten, Teresa, Forero-Torres, Andres, Stringer-Reasor, Erica, Ellis, Erin D., Kaplan, Henry G., Nanda, Rita, Jaskowiak, Nora, Murthy, Rashmi, Godellas, Constantine, Boughey, Judy C., Elias, Anthony D., Haley, Barbara B., Kemmer, Kathleen, Isaacs, Claudine, Clark, Amy S., Lang, Julie E., Lu, Janice, Korde, Larissa, Edmiston, Kirsten K., Northfelt, Donald W., Viscusi, Rebecca K., Yee, Douglas, Perlmutter, Jane, Hylton, Nola M., van’t Veer, Laura J., DeMichele, Angela, Wilson, Amy, Peterson, Garry, Buxton, Meredith B., Paoloni, Melissa, Clennell, Julia, Berry, Scott, Matthews, Jeffrey B., Steeg, Katherine, Singhrao, Ruby, Hirst, Gillian L., Sanil, Ashish, Yau, Christina, Asare, Smita M., Berry, Donald A., Esserman, Laura J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2020
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106976/
https://ncbi.nlm.nih.gov/pubmed/32031889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01027
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia